Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amphetamine,Amphetamine Aspartate,Dextroamphetamine Saccharate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules Pharmaceuticals Inc., Receives ANDA Approval for Amphetamine Mixed Salts ER Capsules
Details : Dextroamphetamine Sulfate is a non-catecholamine sympathomimetic amines with CNS stimulant activity. It is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extr...
Product Name : Amphetamine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2023
Lead Product(s) : Amphetamine,Amphetamine Aspartate,Dextroamphetamine Saccharate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules Pharmaceuticals Receives ANDA Approval for Amphetamine Mixed Salts (IR Tablets)
Details : FDA approved generic of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, for Attention Deficit Hyperactivity Disorder and Narcolepsy.
Product Name : Adderall-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 30, 2021
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Glenmark to Launch Generic Version of Adderall Tablets in the US Market by May 2025
Details : Adderall-Generic is a CNS stimulant, which is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and Narcolepsy.
Product Name : Adderall-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 17, 2025
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives FDA Approval for Generic Version of Adderall XR
Details : Adderall XR-Generic is a combination product of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate & amphetamine sulfate. It is indicated for ADHD.
Product Name : Adderall XR-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Cediprof
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Glenmark will distribute Cediprof's FDA approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), the generic version...
Product Name : Adderall-Generic
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 03, 2023
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Cediprof
Deal Size : Undisclosed
Deal Type : Agreement